Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 2Thoracic 2

Conditions

Prostatic Neoplasms 3Castrate-Resistant Prostate Cancer 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × OGX-011 × Genitourinary × Clear all
NCT01188187 2016-10-14

SYNERGY

Achieve Life Sciences

Phase 3 Completed
1,022 enrolled
Genitourinary

Prostatic Neoplasms

NCT01083615 2016-10-12

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Achieve Life Sciences

Phase 3 Terminated
14 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT01578655 2016-10-12

AFFINITY

Achieve Life Sciences

Phase 3 Completed
630 enrolled
Genitourinary

Prostatic Neoplasms

NCT00327340 2012-10-05

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Achieve Life Sciences

Phase 2 Completed
70 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡